3 semaglutide Month Program (Any Dose) SEMAFIT 3 (tablets)

Co-authors include Jennifer Hwang, DO, Neda Laiteerapong, MD, Elbert Huang, MD, Dariush Mozaffarian, MD, DrPH, A

While the tablet is expected to broaden access to GLP-1 therapies, providers increasingly believe the real competitive advantage will come from delivering long-term patient support rather than simply prescribing medication

Retatrutide at 12mg produced approximately 24% weight loss at 48 weeks compared to tirzepatide at 15mg producing approximately 22% at 72 weeks

immediately report to your health care provider any signs/symptoms of acute kidney injury or persistent/extended nausea, vomiting, and diarrhea

These products can be improperly compounded, incorrectly dosed, or counterfeit